Hillstar Bio
United States
- Boston
- 02/04/2025
- Series A
- $67,000,000
Hillstar Bio is a precision immunology company based in Boston's Seaport neighborhood advancing a portfolio of programs against autoimmune diseases with unmet or underserved medical needs.
- Industry Biotechnology Research
- Website https://hillstarbio.com/
- LinkedIn https://www.linkedin.com/company/hillstar-bio/
Related People
Robert MabryFounder
United States -
Cambridge, Massachusetts
Biotechnology leader with extensive experience working across pharma, biotech, and venture- backed startups. Proven ability to lead cross-functional scientific and technology organizations in biologic discovery and development. Successful track record of driving innovative science and strategy to meet milestones from target discovery to IND yielding multiple biologic programs under clinical evaluation and one approval. Experience leading business development and in/out-licensing efforts, managing external collaborations, and building effective teams across multiple organizations.
Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)